Urinary Inflammatory and Oxidative Stress Biomarkers as Indicators for the Clinical Management of Benign Prostatic Hyperplasia
1
Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 97004, Taiwan
2
Department of Urology, School of Medicine, Tzu Chi University, Hualien 97004, Taiwan
3
Graduate Institute of Pathology, National Taiwan University College of Medicine, Taipei 10051, Taiwan
4
Pathology Department, National Taiwan University Hospital, Taipei 10051, Taiwan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(13), 6516; https://doi.org/10.3390/ijms26136516
Submission received: 20 May 2025
/
Revised: 3 July 2025
/
Accepted: 4 July 2025
/
Published: 6 July 2025
(This article belongs to the Special Issue Oxidative Stress and Inflammation in Health and Disease)
Abstract
Oxidative stress and hypoxia-induced inflammation contribute to benign prostatic hyperplasia (BPH) progression. This study investigated the roles of urinary inflammatory and oxidative stress biomarkers in BPH patients. This prospective study enrolled 62 clinical BPH patients (33 treated medically, 29 surgically) and 20 controls. Symptom scores, uroflowmetry, and urinary biomarker levels were assessed at baseline and three months post-treatment. Before treatment, BPH patients exhibited elevated urinary levels of total antioxidant capacity (TAC), PGE2, IL-1β, and IL-6. Post-treatment, successful outcomes were reported in 63.6% of the medical treatment group and 86.2% of the surgical treatment group, with improvements in symptom scores and urinary flow rate, along with reductions in urinary 8-isoprostane, TAC, and IL-1β. Prior to treatment, voiding efficiency (VE) was negatively correlated with urinary IL-1β, IL-6, and IL-8 levels, while bladder wall thickness was positively correlated with TAC. After treatment, changes in VE were negatively correlated with changes in IL-1β, and changes in post-void residual urine were positively correlated with changes in IL-1β, IL-6, IL-8, and TNF-α. Urinary inflammatory and oxidative stress biomarkers may serve as non-invasive indicators of disease severity and treatment response in clinical BPH. Their significant correlations with clinical improvements underscore their potential utility in monitoring treatment efficacy.
1. Introduction
Lower urinary tract symptoms (LUTS) are highly prevalent and affect more than 60% of men over 40 years of age [1,2]. Clinical benign prostatic hyperplasia (BPH), defined as prostate adenoma/hyperplasia causing bladder outlet obstruction (BOO) [2], is a common cause of male LUTS [3]. BOO can lead to progressive bladder tissue remodeling and potentially serious impairments of the upper urinary tract [4,5]. The development and progression of BOO and its associated urinary dysfunctions are profoundly influenced by cyclic ischemia–reperfusion injury, in which elevated intravesical pressure during voiding induces bladder wall ischemia, followed by reperfusion that generates oxidative stress and triggers hypoxia-related inflammation. This inflammatory microenvironment promotes fibrosis and structural remodeling of bladder tissue, contributing to long-term dysfunction. [5,6].
Oxidative stress, characterized by an imbalance between reactive oxygen species (ROS) and antioxidant defenses, and chronic inflammation have both been increasingly recognized as key contributors in the pathogenesis of BPH [7,8,9]. Prostatic inflammation is driven by multiple overlapping mechanisms, including infection, autoimmune reactions, hormonal alterations, pelvic ischemia, and urine reflux into the prostatic ducts [8]. This inflammatory process contributes to BPH severity by promoting prostatic enlargement and BOO, and inducing storage symptoms. Both chronic inflammation and oxidative stress are thought to actively contribute to BPH progression. Furthermore, tissue hypoxia resulting from BOO is believed to be a major driver of disease advancement, particularly in the context of bladder wall remodeling. Emerging evidence highlights the need for future research to validate oxidative stress-related biomarkers targeting these underlying pathophysiological processes in BPH [9,10].
The significance of oxidative stress biomarkers in BOO, such as 8-hydroxy-2-deoxyguanosine (8-OHdG), F2-isoprostane, and total antioxidant capacity (TAC), was comprehensively reviewed. The alterations in oxidative stress biomarkers associated with BOO and the correlation between oxidative stress and BOO-related urinary dysfunctions were elucidated [6]. Pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α), IL-1β, IL-6, and IL-8, are crucial in hypoxia-related inflammation [11,12], potentially playing a significant role in the progression of BOO. Recently, urinary oxidative stress and inflammatory biomarker profiles were found to be different among male LUTS with different etiologies, suggesting the potential diagnostic utility of these urinary biomarkers [13].
A three-stage model of bladder wall remodeling due to BOO has been hypothesized, which includes an initial hypertrophy phase, followed by a compensation phase, and ultimately progressing to a decompensation phase [5]. In this model, tissue hypoxia is pivotal in driving disease progression. Early medical or surgical intervention could potentially halt this progression. Biomarkers indicative of oxidative stress may offer valuable insights for the diagnosis and intervention approaches, and become a focus of growing research interest.
In this study, we aimed to investigate the roles of urinary inflammatory and oxidative stress biomarkers in clinical BPH patients, examining their correlations with clinical characteristics and treatment outcomes.
2. Results
2.1. Baseline Clinical Characteristics and Urinary Biomarker Profiles
The study enrolled 62 clinical BPH patients (mean age 65.33 ± 6.84 years) and 20 non-age-matched controls (mean age 38.0 ± 7.9 years). Compared with controls, BPH patients exhibited significantly thicker bladder walls (bladder wall thickness [BWT]: 2.48 ± 0.72 mm vs. 1.58 ± 0.33 mm; detrusor wall thickness [DWT]: 1.13 ± 0.48 mm vs. 0.69 ± 0.20 mm), higher International Prostate Symptom Scores (IPSS: 17.42 ± 7.11 vs. 1.20 ± 1.20), lower maximal urinary flow rates (Qmax: 9.07 ± 3.79 mL/s vs. 24.72 ± 7.33 mL/s), lower corrected Qmax (cQmax: 0.57 ± 0.24 vs. 1.30 ± 0.72), smaller voided volumes (Vol: 241.89 ± 120.78 mL vs. 425.1 ± 153.52 mL), and reduced voiding efficiency (VE: 0.87 ± 0.13 vs. 0.95 ± 0.08). Prostate volume was measured only in BPH patients, with a mean of 42.76 ± 14.5 mL (Table 1). No significant intergroup differences were observed between the medical treatment and surgical treatment cohorts in clinical characteristics, symptom scores, or uroflowmetry parameters.
At baseline, urinary biomarker analysis showed that clinical BPH patients had significantly higher levels of TAC, prostaglandin E2 (PGE2), IL-1β, and IL-6 compared to controls (Table 2). Post-hoc power analysis reported 8.7, 18, 65.1, and 48.8% power (with an alpha value of 0.05) in the evaluation of TAC, PGE2, IL-1β, and IL-6 levels, respectively. Among clinical BPH patients, the surgical treatment group exhibited significantly higher baseline urinary PGE2 levels and lower IL-1β levels than the medical treatment group.
2.2. Treatment Outcomes and Changes in Urinary Biomarkers
Following three-month treatment, successful outcomes were achieved in 63.6% of the medical treatment group and 86.2% of the surgical treatment group, with both groups exhibiting significant improvements in symptom scores and uroflowmetry measures (both Qmax and cQmax).
Post-treatment, significant reductions in urinary 8-isoprostane, TAC, and IL-1β levels were observed across the cohort. In subgroup analyses, the medical treatment group showed significant decreases in urinary IL-1β, IL-8, and TNF-α levels, whereas the surgical treatment group demonstrated significant declines in TAC and PGE2 (Table 2).
Within the medical treatment group, 63.6% (21 of 33) of patients achieved successful outcomes (Table 3). These patients experienced substantial improvements in symptom scores and marked reductions in urinary 8-isoprostane, PGE2, IL-1β, and IL-8 levels. Conversely, patients with unsuccessful outcomes exhibited no significant changes in symptom scores, uroflowmetry parameters, or urinary biomarker profiles, except for a decrease in TNF-α levels.
2.3. Correlation Analyses Between Clinical Characteristics and Urinary Biomarkers
Correlation analysis revealed significant associations between clinical parameters and urinary biomarker levels at baseline in the overall clinical BPH cohort (Figure 1). Specifically, VE was negatively correlated with IL-1β, IL-6, and IL-8 levels, while BWT was positively correlated with TAC. After treatment, changes in VE were negatively correlated with changes in IL-1β, and changes in post-void residual urine (PVR) were positively correlated with changes in IL-1β, IL-6, IL-8, and TNF-α (Figure 2). Given the non-normal and right-skewed distribution of IL-1β, IL-6, and IL-8 observed in Figure 1A–C and Figure 2A–B, additional analyses using Spearman’s rank correlation were performed. These supported the directionality of the original findings, although statistical significance was not reached, likely reflecting weaker associations under non-parametric analysis.
Within the medical treatment group, baseline correlation analysis showed that VE was negatively correlated with IL-1β, IL-6, IL-8, and TNF-α levels, whereas BWT was positively correlated with TAC (Supplementary Figure S1). Following treatment, changes in IPSS voiding subscore (IPSS-V) were positively correlated with changes in IL-1β, IL-6, IL-8, and TNF-α levels; changes in VE were negatively correlated with these biomarkers. Moreover, changes in cQmax were negatively correlated with changes in IL-1β and IL-8 levels (Supplementary Figure S2).
Supplementary Figure S3 presents baseline and post-treatment correlation analyses between clinical characteristics and urinary biomarker levels in the surgical treatment group.
3. Discussion
This study demonstrated significant correlations between clinical characteristics and urinary biomarker levels, as well as between their respective changes following treatment, in clinically diagnosed BPH patients undergoing medical or surgical interventions. Notably, a marked decrease in urinary biomarkers was observed in BPH patients after treatment. In particular, within the medical treatment group, a greater number of urinary biomarkers showed significant reductions in patients who achieved successful outcomes compared to those with unsuccessful outcomes. These findings suggest that urinary biomarkers may serve as potential indicators of disease severity and treatment response. Furthermore, the post-treatment reductions in urinary biomarkers were aligned with improvements in clinical symptom scores and enhanced urinary flow rates, further supporting the notion that oxidative stress and inflammation play critical roles in the pathophysiology of clinical BPH [8,9].
The complex interplay between chronic inflammation and oxidative stress contributes to the progression of BPH [9]. The detection of urinary inflammatory mediators in BPH patients has the potential to distinguish BPH-related pathologies, assess the risk of disease progression, and enable personalized management of BPH-associated LUTS [10,14]. In this study, prior to treatment, clinical BPH patients exhibited significantly higher urinary levels of TAC, PGE2, IL-1β, and IL-6 compared to controls, supporting the concept of an elevated oxidative and inflammatory state in this patient population. Furthermore, VE negatively correlated with hypoxia-related inflammatory biomarkers (IL-1β, IL-6, and IL-8) (Figure 1A–C), suggesting that increased hypoxia-related inflammation is associated with impaired bladder function. This is in line with previous findings that urinary levels of chemokines were associated with varying degrees of LUTS severity [15]. Additionally, a positive correlation between BWT and urinary TAC levels was observed (Figure 1D), suggestive of a structural adaptation of the bladder wall in response to oxidative stress. These findings are consistent with the proposed sequence whereby BOO leads to tissue hypoxia and oxidative stress, which in turn drive the structural remodeling of the bladder wall, manifesting as increased BWT. This remodeling includes smooth muscle hypertrophy, collagen accumulation, and mitochondrial dysfunction, as previously described [5,16].
In this study, after treatment for BPH, changes in VE were negatively correlated with changes in IL-1β, and changes in PVR were positively correlated with changes in IL-1β, IL-6, IL-8, and TNF-α (Figure 2). These findings suggest that improvements in bladder function are associated with reductions in urinary inflammatory biomarkers. Based on these observations, we propose that the treatment of BPH alleviates BOO, thereby improving bladder emptying efficiency and ameliorating oxidative stress and hypoxia-induced inflammation within the urinary bladder, as reflected by decreases in urinary biomarker levels. This interpretation is supported by recent evidence showing that surgical de-obstruction in BPH patients leads to a substantial, although incomplete, reversal of bladder remodeling at the molecular level, alongside improvements in urodynamic parameters [17]. Animal studies further support the reversibility of BOO-induced inflammation and oxidative stress. The relief of obstruction has been shown to reduce inflammatory cytokines and regulatory T cells [18], while oxidative stress markers such as 8-OHdG and malondialdehyde progressively return toward baseline following de-obstruction [19,20].
Notably, differences in urinary biomarker changes were observed between the medical treatment and surgical treatment groups in this study. Medical treatment was associated with significant reductions in inflammatory markers (IL-1β, IL-8, and TNF-α), suggesting that alleviating inflammation plays a major role in clinical improvement. This interpretation is supported by both clinical and experimental studies. Phytotherapeutic agents such as Eviprostat have been shown to reduce urinary oxidative stress markers and improve LUTS [21]. In addition, α1-adrenoreceptor antagonists like silodosin attenuate urine-induced prostatic inflammation and oxidative stress by improving prostatic microcirculation [22].
Conversely, in this study, surgical treatment led to greater decreases in oxidative stress markers (TAC) and PGE2, reflecting the more significant mechanical relief of BOO and restoration of bladder oxygenation. This is in line with recent evidence showing that surgical de-obstruction of the bladder outlet leads to the reversal of bladder wall remodeling, as demonstrated by normalized transcriptional regulators and improved urodynamic parameters [17]. Similar reductions in urinary nerve growth factor and improvements in LUTS after TURP have also been reported [23]. These distinct biomarker response patterns, the inflammation-focused effect of medical treatment and the oxidative stress-related improvements seen after surgery, highlight the differing biological responses associated with medical and surgical treatments for BPH.
This study supports the hypothesis of the impact of BOO on bladder wall remodeling, delineated into three distinct phases: hypertrophy, compensation, and decompensation [5]. Tissue hypoxia, driven by cyclic ischemia–reperfusion injury, plays a critical role in this progression by activating inflammatory pathways and influencing signaling pathways related to angiogenesis, cell proliferation, and extracellular matrix remodeling. These molecular and physiological alterations result in morphological changes and functional impairments in bladder voiding, which may be reflected by changes in urinary biomarker profiles. Our findings align with this pathophysiological model, as elevated urinary levels of inflammatory markers in BPH patients were associated with impaired voiding function, such as lower VE. Notably, distinct urinary biomarker response patterns were observed between medical treatment and surgical treatment groups, suggesting different mechanisms of therapeutic effect—primarily inflammation resolution following medical therapy and oxidative stress reduction after surgical de-obstruction.
This study had several limitations. First, the follow-up period was relatively short, and the sample size was limited, particularly after stratifying patients into medical and surgical groups, which may have affected the statistical power to detect subgroup differences. Second, there might be inter-individual and intra-individual variations that were not fully controlled. Third, our controls were stringently selected based on symptom scores and uroflowmetry to best approximate normal lower urinary tract function. As a result, age-matching was not performed, and the age difference between groups may introduce bias. Fourth, follow-up urinary biomarker measurements were not performed in the control group, as these participants were asymptomatic and not undergoing any clinical intervention. This design aimed to minimize unnecessary procedures and reduce participant burden, but limits the interpretation of intra-individual biomarker variability over time in controls. Finally, treatment selection was based on patient preference, which could introduce selection bias. In addition, future studies should consider incorporating additional assays—such as the direct quantification of ROS or the use of cumulative ROS detection kits—to better delineate oxidative stress mechanisms.
4. Materials and Methods
4.1. Patients
From November 2020 to July 2022, we prospectively enrolled 62 male patients with voiding-symptom-predominant LUTS and the clinical diagnosis of BPH at the department of urology of a single medical center. The inclusion criteria included age ≥ 40 years of age, IPSS ≥ 12 points, TPV > 30 mL, IPSS-V > IPSS storage subscore (IPSS-S), and Qmax < 15 mL/s with a bladder capacity (defined as Vol plus PVR) ≥ 150 mL. Exclusion criteria included active urinary tract infection, acute or chronic prostatitis, interstitial cystitis, neurogenic voiding dysfunction, urinary tract urolithiasis, a history of urinary tract malignancy or tuberculosis, a history of urinary tract surgery/or traumatic injury, a history of urethral stricture, a history of nephrotic or nephritic syndrome, and impaired renal function (serum Cre > 2.0 mg/dL).
We invited 20 healthy men, who were ready to receive circumcision, vasectomy, or inguinal hernia repair in the same department of urology, to serve as controls. Eligible controls were aged ≥ 20 years old, without significant storage or voiding symptoms (IPSS < 6 points), and with normal uroflowmetry results (defined as Qmax ≥ 18 mL/s, Vol ≥ 350mL, and PVR < 50 mL). A detailed flowchart of the study enrollment process is presented in Supplementary Figure S4.
4.2. Clinical Assessment and Follow-Up
All study patients and controls received clinical assessment on enrollment, including IPSS, IPSS-V, IPSS-S, quality of life score, overactive bladder symptoms score, the measurement of DWT and BWT [24], and uroflowmetry and PVR. Study patients but not controls received a trans-rectal ultrasound of the prostate for the measurement of the prostate size.
Study patients were divided into medical treatment and surgical treatment groups. Medical treatment group patients were treatment-naïve and received alpha blockers (including options such as tamsulosin and silodosin) for 3 months; 5-alpha reductase inhibitors were not administered in this study. Surgical treatment group patients had refractory LUTS and were ready to receive the surgery of transurethral resection of the prostate. Clinical symptom scores, uroflowmetry and PVR, and global response assessment (GRA) for treatment outcome evaluation were assessed at 3 months after treatment. GRA was categorized as −3, −2, −1, 0, 1, 2, and 3, which indicated markedly worse to markedly improved status based on satisfaction after treatment. A successful outcome was defined as a GRA score of ≥ 2 (moderately and markedly improved) [25].
4.3. Assessment of Urinary Biomarker Levels
Urine samples were collected from study patients and controls on enrollment, and from study patients at 3 months after treatment. Urine was self-voided by patients who had a full bladder sensation. Then, urinalysis was performed simultaneously to confirm an infection-free status before urine samples were stored. The preparation procedures for urine samples were similar to those reported in the previous study [26]. In total, 50 mL urine samples were placed on ice immediately and transferred to the laboratory for preparation. The samples were centrifuged at 1800 rpm for 10 min at 4 °C. The supernatant was separated into aliquots in 1.5 mL tubes (1 mL per tube) and was preserved in a freezer at −80 °C. Before further analyses were performed, the frozen urine samples were centrifuged at 12,000 rpm for 15 min at 4 °C, and the supernatants were used for subsequent evaluations.
4.4. Quantification of Urinary Oxidative Stress Biomarkers
The targeted analytes of oxidative stress biomarkers included 8-OHdG, 8-isoprostane, and TAC. The quantification of 8-OHdG, 8-isoprostane, and TAC in urine samples was performed in accordance with the respective manufacturer’s instructions (8-OHdG ELISA Kit, BioVision, Waltham, MA, USA; 8 isoprostane ELIZA kit, Enzo Life Sciences, Farmingdale, NY, USA; Total Antioxidant Capacity Assay Kit, abcam, Cambridge, UK). The laboratory procedures for the quantification of these targeted analytes were similar to those reported in the previous study [26].
4.5. Quantification of Urinary Inflammatory Biomarkers
The targeted analytes of hypoxia-related inflammatory biomarkers included IL-1β, IL-6, IL-8, and TNF-α, which were assayed using a Milliplex® (Darmstadt, Germany) human cytokine/chemokine magnetic bead-based panel kit (catalog number HCYTMAG-60K, Millipore, Darmstadt, Germany). The following laboratory procedures for the quantification of these targeted analytes were similar to those reported in previous studies [26,27].
Urinary PGE2 level was measured using a high-sensitivity ELISA kit (Cayman, MI, USA), according to the manufacturer’s instructions. The laboratory procedures for the quantification of PGE2 were similar to those reported in the previous study [28].
4.6. Statistical Analysis
Continuous variables in clinical assessment were presented as means ± standard deviations and categorical variables as numbers and percentages. The data for urinary biomarker levels were presented with the median and interquartile range. Continuous clinical data were compared using independent t-tests for two-group comparisons (e.g., study vs. control, and medical treatment vs. surgical treatment). The levels of urinary biomarkers for comparison were analyzed using the Mann–Whitney U test for two-group comparisons. Prior to correlation analysis, the normality of variable distributions was assessed. Pearson correlation analysis was applied for normally distributed variables, while Spearman’s rank correlation was used for variables with non-normal, right-skewed distributions (e.g., IL-1β, IL-6, and IL-8). A post-hoc power calculation was performed for biomarkers with significant differences between the study and control groups. All calculations were performed using SPSS Statistics software for Windows version 20.0 (IBM Corp., Armonk, NY, USA). If the p-value is less than 0.05, the difference is considered statistically significant.
5. Conclusions
This study provides evidence of the diagnostic and prognostic values of urinary inflammatory and oxidative stress biomarkers in managing clinical BPH patients. These biomarkers may serve as indicators of disease severity and treatment response, offering insights into the underlying pathophysiological mechanisms and the effectiveness of both medical and surgical interventions.
Supplementary Materials
The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/ijms26136516/s1.
Author Contributions
Conceptualization, Y.-H.J.; methodology, Y.-H.J.; formal analysis, J.L.; investigation, Y.-H.W.; resources, Y.-H.J.; data curation, Y.-H.J. and Y.-H.W.; writing—original draft preparation, Y.-H.J.; writing—review and editing, J.L. and H.-C.K.; supervision, Y.-H.J.; project administration, Y.-H.J.; funding acquisition, Y.-H.J. All authors have read and agreed to the published version of the manuscript.
Funding
This study was funded by the Ministry of Science and Technology (Taiwan) with grant number MOST 109-2628-B-303-002-.
Institutional Review Board Statement
The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board and Ethics Committee of Buddhist Tzu Chi General Hospital (No. IRB108-270-A, approval date 25 February 2020). All procedures were carried out in accordance with the relevant guidelines and regulations.
Informed Consent Statement
We informed all study patients and controls about the risks, rationale, procedures, ethics, and costs of this study, and they provided informed consent.
Data Availability Statement
The original contributions presented in this study are included in the article/Supplementary Materials. Further inquiries can be directed to the corresponding author.
Conflicts of Interest
The authors declare no conflicts of interest.
References
- Liu, S.P.; Chuang, Y.C.; Sumarsono, B.; Chang, H.C. The prevalence and bother of lower urinary tract symptoms in men and women aged 40 years or over in Taiwan. J. Formos. Med. Assoc. 2019, 118, 170–178. [Google Scholar] [CrossRef] [PubMed]
- Foo, K.T. What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? World J. Urol. 2019, 37, 1293–1296. [Google Scholar] [CrossRef] [PubMed]
- Lee, C.-L.; Kuo, H.-C. Videourodynamic analysis in men with lower urinary tract symptoms: Correlation between age and prostate size with lower urinary tract dysfunction. Urol. Sci. 2016, 27, 21–25. [Google Scholar] [CrossRef]
- Mirone, V.; Imbimbo, C.; Longo, N.; Fusco, F. The detrusor muscle: An innocent victim of bladder outlet obstruction. Eur. Urol. 2007, 51, 57–66. [Google Scholar] [CrossRef]
- Fusco, F.; Creta, M.; De Nunzio, C.; Iacovelli, V.; Mangiapia, F.; Li Marzi, V.; Finazzi Agro, E. Progressive bladder remodeling due to bladder outlet obstruction: A systematic review of morphological and molecular evidences in humans. BMC Urol. 2018, 18, 15. [Google Scholar] [CrossRef]
- Miyata, Y.; Matsuo, T.; Mitsunari, K.; Asai, A.; Ohba, K.; Sakai, H. A Review of Oxidative Stress and Urinary Dysfunction Caused by Bladder Outlet Obstruction and Treatments Using Antioxidants. Antioxidants 2019, 8, 132. [Google Scholar] [CrossRef]
- Bostanci, Y.; Kazzazi, A.; Momtahen, S.; Laze, J.; Djavan, B. Correlation between benign prostatic hyperplasia and inflammation. Curr. Opin. Urol. 2013, 23, 5–10. [Google Scholar] [CrossRef]
- Inamura, S.; Terada, N. Chronic inflammation in benign prostatic hyperplasia: Pathophysiology and treatment options. Int. J. Urol. 2024, 31, 968–974. [Google Scholar] [CrossRef]
- Kaltsas, A.; Giannakas, T.; Stavropoulos, M.; Kratiras, Z.; Chrisofos, M. Oxidative Stress in Benign Prostatic Hyperplasia: Mechanisms, Clinical Relevance and Therapeutic Perspectives. Diseases 2025, 13, 53. [Google Scholar] [CrossRef]
- Tyagi, P.; Wang, Z.; Yoshimura, N. Urinary Biomarkers and Benign Prostatic Hyperplasia. Curr. Bladder Dysfunct. Rep. 2019, 14, 31–40. [Google Scholar] [CrossRef]
- Schieber, M.; Chandel, N.S. ROS function in redox signaling and oxidative stress. Curr. Biol. 2014, 24, R453–R462. [Google Scholar] [CrossRef] [PubMed]
- Malkov, M.I.; Lee, C.T.; Taylor, C.T. Regulation of the Hypoxia-Inducible Factor (HIF) by Pro-Inflammatory Cytokines. Cells 2021, 10, 2340. [Google Scholar] [CrossRef] [PubMed]
- Yu, W.R.; Jiang, Y.H.; Jhang, J.F.; Kuo, H.C. Use of Urinary Biomarkers in Discriminating Interstitial Cystitis/Bladder Pain Syndrome from Male Lower Urinary Tract Dysfunctions. Int. J. Mol. Sci. 2023, 24, 12055. [Google Scholar] [CrossRef] [PubMed]
- Tyagi, P.; Motley, S.S.; Koyama, T.; Kashyap, M.; Gingrich, J.; Yoshimura, N.; Fowke, J.H. Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients. Prostate 2018, 78, 17–24. [Google Scholar] [CrossRef]
- Tyagi, P.; Motley, S.S.; Kashyap, M.; Pore, S.; Gingrich, J.; Wang, Z.; Yoshimura, N.; Fowke, J.H. Urine chemokines indicate pathogenic association of obesity with BPH/LUTS. Int. Urol. Nephrol. 2015, 47, 1051–1058. [Google Scholar] [CrossRef]
- Komninos, C.; Mitsogiannis, I. Obstruction-induced alterations within the urinary bladder and their role in the pathophysiology of lower urinary tract symptomatology. Can. Urol. Assoc. J. 2014, 8, E524–E530. [Google Scholar] [CrossRef]
- Akshay, A.; Gheinani, A.H.; Besic, M.; Braga, S.; Uldry, A.C.; Heller, M.; Rehrauer, H.; Fournier, C.A.; Burkhard, F.C.; Monastyrskaya, K. De-obstruction of bladder outlet in humans reverses organ remodelling by normalizing the expression of key transcription factors. BMC Urol. 2024, 24, 33. [Google Scholar] [CrossRef]
- Lin, W.Y.; Lin, Y.P.; Levin, R.M.; Chen, M.L. The relevance of immune responses to partial bladder outlet obstruction and reversal. Neurourol. Urodyn. 2017, 36, 1306–1312. [Google Scholar] [CrossRef]
- Lin, W.Y.; Wu, S.B.; Lin, Y.P.; Chang, P.J.; Levin, R.M.; Wei, Y.H. Reversing bladder outlet obstruction attenuates systemic and tissue oxidative stress. BJU Int. 2012, 110, 1208–1213. [Google Scholar] [CrossRef]
- Di Minno, A.; Aveta, A.; Gelzo, M.; Tripodi, L.; Pandolfo, S.D.; Crocetto, F.; Imbimbo, C.; Castaldo, G. 8-Hydroxy-2-Deoxyguanosine and 8-Iso-Prostaglandin F2alpha: Putative Biomarkers to assess Oxidative Stress Damage Following Robot-Assisted Radical Prostatectomy (RARP). J. Clin. Med. 2022, 11, 6102. [Google Scholar] [CrossRef]
- Matsumoto, S.; Hanai, T.; Matsui, T.; Oka, M.; Tanaka, M.; Uemura, H. Eviprostat suppresses urinary oxidative stress in a rabbit model of partial bladder outlet obstruction and in patients with benign prostatic hyperplasia. Phytother. Res. 2010, 24, 301–303. [Google Scholar] [CrossRef] [PubMed]
- Funahashi, Y.; Majima, T.; Matsukawa, Y.; Yamamoto, T.; Yoshida, M.; Gotoh, M. Intraprostatic Reflux of Urine Induces Inflammation in a Rat. Prostate 2017, 77, 164–172. [Google Scholar] [CrossRef] [PubMed]
- Hu, H.; Zhang, W.; Liu, X.; Wang, H.; Fang, Z.; Liang, C.; Wang, T.; Xu, K. Nerve Growth Factor Levels are Associated with Overactive Bladder Symptoms and Long-Term Treatment Outcome after Transurethral Resection of the Prostate in Patients with Benign Prostatic Hyperplasia. J. Urol. 2018, 200, 620–625. [Google Scholar] [CrossRef] [PubMed]
- Manieri, C.; Carter, S.S.; Romano, G.; Trucchi, A.; Valenti, M.; Tubaro, A. The diagnosis of bladder outlet obstruction in men by ultrasound measurement of bladder wall thickness. J. Urol. 1998, 159, 761–765. [Google Scholar] [CrossRef]
- Nickel, J.C.; O’Leary, M.P.; Lepor, H.; Caramelli, K.E.; Thomas, H.; Hill, L.A.; Hoel, G.E. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: Results of a phase II multicenter, double-blind, placebo controlled study. J. Urol. 2011, 186, 125–131. [Google Scholar] [CrossRef]
- Jiang, Y.H.; Jhang, J.F.; Ho, H.C.; Hsu, Y.H.; Kuo, H.C. Diagnostic and prognostic value of urine biomarkers among women with dysfunctional voiding. Sci. Rep. 2022, 12, 6608. [Google Scholar] [CrossRef]
- Jiang, Y.H.; Jhang, J.F.; Hsu, Y.H.; Ho, H.C.; Wu, Y.H.; Kuo, H.C. Urine cytokines as biomarkers for diagnosing interstitial cystitis/bladder pain syndrome and mapping its clinical characteristics. Am. J. Physiol. Ren. Physiol. 2020, 318, F1391–F1399. [Google Scholar] [CrossRef]
- Chen, S.F.; Jiang, Y.H.; Kuo, H.C. Urinary biomarkers in patients with detrusor underactivity with and without bladder function recovery. Int. Urol. Nephrol. 2017, 49, 1763–1770. [Google Scholar] [CrossRef]
Figure 1.
Scatter plots showing the correlations of the clinical characteristics and the baseline urinary biomarker levels in the clinical BPH (both medical and surgical groups) patients. Correlations between VE and IL-1β (A), VE and IL-6 (B), VE and IL-8 (C), and BWT and TAC (D). VE, voiding efficiency; BWT, bladder wall thickness; and TAC, total antioxidant capacity.
Figure 1.
Scatter plots showing the correlations of the clinical characteristics and the baseline urinary biomarker levels in the clinical BPH (both medical and surgical groups) patients. Correlations between VE and IL-1β (A), VE and IL-6 (B), VE and IL-8 (C), and BWT and TAC (D). VE, voiding efficiency; BWT, bladder wall thickness; and TAC, total antioxidant capacity.
Figure 2.
Scatter plots showing the correlations of the changes in clinical characteristics and the changes in urine biomarker levels in clinical BPH (both medical and surgical groups) patients. Correlations between ΔVE and ΔIL-1β (A), ΔPVR and ΔIL-1β (B), ΔPVR and ΔIL-6 (C), ΔPVR and ΔIL-8 (D), and ΔPVR and ΔTNF-α (E). Δ, change in [specific variable]; VE, voiding efficiency; PVR, post-void residual urine; and TNF-α, tumor necrosis factor-α.
Figure 2.
Scatter plots showing the correlations of the changes in clinical characteristics and the changes in urine biomarker levels in clinical BPH (both medical and surgical groups) patients. Correlations between ΔVE and ΔIL-1β (A), ΔPVR and ΔIL-1β (B), ΔPVR and ΔIL-6 (C), ΔPVR and ΔIL-8 (D), and ΔPVR and ΔTNF-α (E). Δ, change in [specific variable]; VE, voiding efficiency; PVR, post-void residual urine; and TNF-α, tumor necrosis factor-α.
Table 1.
Clinical characteristics, symptom scores, and uroflowmetry data between clinical BPH patients and controls.
Table 1.
Clinical characteristics, symptom scores, and uroflowmetry data between clinical BPH patients and controls.
| Clinical BPH | |||||||
|---|---|---|---|---|---|---|---|
| Medical Treatment Group N = 33 | Surgical Treatment Group N = 29 | Overall N = 62 | Control N = 20 | p-Value $ | p-Value # | ||
| Age | 64.28 ± 7.12 | 66.88 ± 6.19 | 65.33 ± 6.84 | 38.0 ± 7.9 | <0.001 | 0.087 | |
| PSA (ng/mL) | 2.41 ± 1.95 | 2.95 ± 2.66 | 2.63 ± 2.26 | 0.287 | 0.287 | ||
| TPV (mL) | 41.4 ± 13.05 | 44.76 ± 16.41 | 42.76 ± 14.5 | 0.300 | 0.300 | ||
| TZI | 0.41 ± 0.11 | 0.44 ± 0.11 | 0.43 ± 0.11 | 0.230 | 0.230 | ||
| DWT (mm) | 1.17 ± 0.54 | 1.08 ± 0.38 | 1.13 ± 0.48 | 0.69 ± 0.20 | <0.001 | 0.410 | |
| BWT (mm) | 2.53 ± 0.81 | 2.42 ± 0.57 | 2.48 ± 0.72 | 1.58 ± 0.33 | <0.001 | 0.467 | |
| Symptom scores | |||||||
| IPSS-V | Baseline | 11.08 ± 5.31 | 12.35 ± 4.91 | 11.60 ± 5.16 | 0.50 ± 0.89 | <0.001 | 0.270 |
| Δ at 3mo | −3.48 ± 5.96 * | −9.62 ± 6.55 * | −6.35 ± 6.92 * | <0.001 | |||
| IPSS-S | Baseline | 5.20 ± 3.84 | 6.74 ± 4.19 | 5.82 ± 4.04 | 0.70 ± 1.030 | <0.001 | 0.087 |
| Δ at 3mo | −1.91 ± 3.6 * | −3.17 ± 4.18 * | −2.50 ± 3.90 * | 0.206 | |||
| IPSS | Baseline | 16.28 ± 7 | 19.09 ± 7.03 | 17.42 ± 7.11 | 1.20 ± 1.20 | <0.001 | 0.075 |
| Δ at 3mo | −5.39 ± 7.16 * | −12.79 ± 9.50 * | −8.85 ± 9.06 * | 0.001 | |||
| QoL | Baseline | 3.62 ± 1.1 | 3.97 ± 1.27 | 3.76 ± 1.18 | 0.65 ± 0.75 | <0.001 | 0.182 |
| Δ at 3mo | −1.09 ± 1.65 * | −2.31 ± 1.51 * | −1.66 ± 1.69 * | 0.004 | |||
| OABSS | Baseline | 4.52 ± 3.52 | 5.32 ± 3.20 | 4.85 ± 3.40 | 0.65 ± 0.67 | <0.001 | 0.290 |
| Δ at 3mo | −2.06 ± 3.77 * | −1.69 ± 3.63 * | −1.89 ± 3.68 * | 0.696 | |||
| Uroflowmetry | |||||||
| BC (mL) | Baseline | 301.15 ± 179.27 | 263.83 ± 119.17 | 286.59 ± 158.78 | 441.71 ± 156.22 | <0.001 | 0.302 |
| Δ at 3mo | 25.55 ± 173.73 | −14.17 ± 85.88 | 6.4 ± 138.76 | 0.280 | |||
| Qmax (mL/s) | Baseline | 9.72 ± 3.43 | 8.05 ± 4.14 | 9.07 ± 3.79 | 24.72 ± 7.33 | <0.001 | 0.051 |
| Δ at 3mo | 1.09 ± 5.41 | 6.06 ± 5.68 * | 3.49 ± 6.04 * | 0.001 | |||
| cQmax | Baseline | 0.6 ± 0.21 | 0.53 ± 0.28 | 0.57 ± 0.24 | 1.30 ± 0.72 | <0.001 | 0.225 |
| Δ at 3mo | 0.03 ± 0.28 | 0.4 ± 0.37 * | 0.21 ± 0.37 * | <0.001 | |||
| Vol (mL) | Baseline | 259.86 ± 131.37 | 213.81 ± 97.49 | 241.89 ± 120.78 | 425.1 ± 153.52 | <0.001 | 0.092 |
| Δ at 3mo | 13.1 ± 116.06 | 14.7 ± 80.43 | 13.88 ± 99.58 | 0.953 | |||
| PVR (mL) | Baseline | 41.3 ± 105.39 | 50.03 ± 54.45 | 44.71 ± 88.72 | 16.65 ± 21.62 | 0.342 | 0.667 |
| Δ at 3mo | 12.45 ± 198.92 | −28.85 ± 60.24 | −7.46 ± 149.31 | 0.305 | |||
| VE | Baseline | 0.89 ± 0.11 | 0.83 ± 0.16 | 0.87 ± 0.13 | 0.95 ± 0.08 | 0.005 | 0.086 |
| Δ at 3mo | −0.03 ± 0.21 | 0.08 ± 0.18 * | 0.02 ± 0.2 | 0.054 |
*: p < 0.05 when compared with baseline data. $: p-value between overall clinical BPH patients and controls. #: p-value between medical treatment group, and surgical treatment group of clinical BPH patients. Δ: change in [specific variable]. BPH, benign prostatic hyperplasia; PSA, prostate-specific antigen; TPV, total prostate volume; TZI, transitional zone index; DWT, detrusor wall thickness; BWT, bladder wall thickness; IPSS, International Prostate Symptom Score; IPSS-S, IPSS storage subscore; IPSS-V, IPSS voiding subscore; QoL, quality of life; OABSS, overactive bladder symptoms score; BC, bladder capacity; Qmax, maximal urinary flow rate; cQmax, corrected maximal urinary flow rate; Vol, voided volume; PVR, post-void residual urine; and VE, voiding efficiency.
Table 2.
Urinary biomarker levels between clinical BPH patients and controls.
| Clinical BPH | |||||||
|---|---|---|---|---|---|---|---|
| Medical Treatment Group N = 33 | Surgical Treatment Group N = 29 | Overall N = 62 | Control N = 20 | p-Value $ | p-Value # | ||
| Urine biomarkers @ | |||||||
| 8-OHdG | Baseline | 79.83 (29.65, 110.22) | 102.65 (39.43, 132.08) | 85.31 (36.51, 118.61) | 65.1 (54.95, 89.19) | 0.136 | 0.505 |
| Δ at 3mo | −1.05 (−41.38, 13.44) | 9.45 (−26.23, 47.85) | 1.75 (−40.18, 31.69) | 0.121 | |||
| 8-isoprostane | Baseline | 11.88 (7.59, 26.73) | 16.6 (9.56, 30.2) | 14.16 (8.98, 29.82) | 20.72 (12.86, 30.68) | 0.057 | 0.266 |
| Δ at 3mo | −2.88 (−8.18, 2.73) | −4.12 (−21.24, 12.31) | −4.11 (−14.03, 4.66) * | 1.000 | |||
| TAC | Baseline | 262.65 (179.62, 446.77) | 316.41 (198.45, 585.2) | 282.56 (195, 489.78) | 167.03 (103.82, 416.68) | 0.045 | 0.266 |
| Δ at 3mo | −23.18 (−136.51, 65.94) | −64.7 (−443.65, 65.08) * | −47.81 (−207.97, 64.13) * | 0.605 | |||
| PGE2 | Baseline | 166.95 (119.72, 301.06) | 271.32 (185.2, 409.52) | 218.92 (124.77, 339.98) | 128.58 (87.85, 367.99) | 0.003 | 0.004 |
| Δ at 3mo | −29.6 (−110.92, 75.02) | −64.71 (−223.72, 49.56) * | −39.84 (−157.77, 57.78) | 0.605 | |||
| IL-1β | Baseline | 0.55 (0.41, 0.61) | 0.48 (0.36, 0.55) | 0.54 (0.39, 0.58) | 0.5 (0.44, 0.51) | 0.002 | 0.009 |
| Δ at 3mo | −0.06 (−0.14, 0.02) * | −0.05 (−0.1, 0.06) | −0.06 (−0.11, 0.04) * | 1.000 | |||
| IL-6 | Baseline | 0.64 (0.35, 1.88) | 1.17 (0.37, 3.39) | 0.73 (0.35, 2.36) | 0.3 (0.16, 0.73) | 0.045 | 0.266 |
| Δ at 3mo | −0.09 (−0.57, 0.1) | 0.4 (−1.24, 6.73) | −0.04 (−0.61, 1.79) | 0.121 | |||
| IL-8 | Baseline | 1.28 (0.48, 3.15) | 1.31 (0.28, 5.56) | 1.28 (0.36, 3.63) | 0.27 (0.14, 1.12) | 0.136 | 0.824 |
| Δ at 3mo | −0.37 (−1.65, 0.38) * | 1.07 (−0.85, 15.94) | −0.05 (−1.34, 1.54) | 0.121 | |||
| TNF-α | Baseline | 1.08 (0.95, 1.25) | 1.06 (0.31, 1.22) | 1.08 (0.69, 1.24) | 1.17 (1.11, 1.17) | 0.234 | 0.824 |
| Δ at 3mo | −0.1 (−0.22, 0.04) * | 0 (−0.16, 0.13) | −0.05 (−0.16, 0.09) | 0.121 |
*: p < 0.05 when compared with baseline data. $: p-value between overall clinical BPH patients and controls. #: p-value between medical treatment group, and surgical treatment group of clinical BPH patients. Δ: change in [specific variable]. @: units are all pg/mL, except ng/mL in 8-OHdG, and nmol/μL in TAC 8-OHdG, 8-hydroxy-2-deoxyguanosine. TAC, total antioxidant capacity; PGE2, prostaglandin E2; and TNF-α, tumor necrosis factor-α.
Table 3.
Clinical characteristics, symptom scores, uroflowmetry data, and urinary biomarker levels in the medical treatment group of clinical BPH patients with different treatment outcomes.
Table 3.
Clinical characteristics, symptom scores, uroflowmetry data, and urinary biomarker levels in the medical treatment group of clinical BPH patients with different treatment outcomes.
| Medical Treatment Group of Clinical BPH Patients | |||||
|---|---|---|---|---|---|
| (A) GRA < 2 (N = 12, 36.4%) | (B) GRA ≥ 2 (N = 21, 63.6%) | Overall N = 33 | p-Value | ||
| Age | 65.58 ± 7.65 | 66 ± 6.46 | 65.85 ± 6.8 | 0.869 | |
| PSA (ng/mL) | 3.79 ± 2.78 | 2.27 ± 1.68 | 2.82 ± 2.23 | 0.059 | |
| TPV (mL) | 47.51 ± 18.42 | 42.19 ± 11.28 | 44.12 ± 14.25 | 0.310 | |
| TZI | 0.43 ± 0.12 | 0.43 ± 0.13 | 0.43 ± 0.12 | 0.944 | |
| DWT (mm) | 1.04 ± 0.5 | 1.38 ± 0.61 | 1.26 ± 0.59 | 0.117 | |
| BWT (mm) | 2.46 ± 0.81 | 2.76 ± 0.79 | 2.65 ± 0.8 | 0.300 | |
| Symptom scores | |||||
| IPSS-V | Baseline | 9.08 ± 5.14 | 12.05 ± 5.55 | 10.97 ± 5.51 | 0.140 |
| Δ at 3mo | −0.75 ± 4.03 | −5.05 ± 6.39 * | −3.48 ± 5.96 * | 0.044 | |
| IPSS-S | Baseline | 6.08 ± 3.5 | 6.48 ± 3.97 | 6.33 ± 3.76 | 0.778 |
| Δ at 3mo | −0.25 ± 3.17 | −2.86 ± 3.55 * | −1.91 ± 3.6 * | 0.043 | |
| IPSS | Baseline | 15.17 ± 7.53 | 18.52 ± 7.15 | 17.3 ± 7.35 | 0.212 |
| Δ at 3mo | −1 ± 4.82 | −7.9 ± 7.14 * | −5.39 ± 7.16 * | 0.006 | |
| QoL | Baseline | 3.92 ± 1.31 | 3.67 ± 1.15 | 3.76 ± 1.2 | 0.573 |
| Δ at 3mo | −0.33 ± 1.5 | −1.52 ± 1.6 * | −1.09 ± 1.65 * | 0.044 | |
| OABSS | Baseline | 5.75 ± 4.14 | 5.1 ± 3.39 | 5.33 ± 3.63 | 0.626 |
| Δ at 3mo | −0.58 ± 3.32 | −2.9 ± 3.83 * | −2.06 ± 3.77 * | 0.089 | |
| Uroflowmetry | |||||
| BC (mL) | Baseline | 250.3 ± 126.14 | 286.19 ± 199.48 | 273.14 ± 175.06 | 0.579 |
| Δ at 3mo | 26.22 ± 214.13 | 25.25 ± 158.66 | 25.55 ± 173.73 | 0.989 | |
| Qmax (mL/s) | Baseline | 8.68 ± 3.36 | 9.6 ± 4.19 | 9.26 ± 3.88 | 0.520 |
| Δ at 3mo | −1.47 ± 2.9 | 2.24 ± 5.92 | 1.09 ± 5.41 | 0.088 | |
| cQmax | Baseline | 0.58 ± 0.19 | 0.6 ± 0.25 | 0.59 ± 0.23 | 0.723 |
| Δ at 3mo | −0.04 ± 0.25 | 0.06 ± 0.29 | 0.03 ± 0.28 | 0.402 | |
| Vol (mL) | Baseline | 229.33 ± 119.81 | 224.05 ± 86.25 | 225.97 ± 97.93 | 0.884 |
| Δ at 3mo | −64.78 ± 89.44 | 48.15 ± 110.98 | 13.1 ± 116.06 | 0.012 | |
| PVR (mL) | Baseline | 21 ± 15.7 | 62.14 ± 158.54 | 47.18 ± 127.27 | 0.380 |
| Δ at 3mo | 91 ± 238.18 | −22.9 ± 173.74 | 12.45 ± 198.92 | 0.157 | |
| VE | Baseline | 0.91 ± 0.08 | 0.85 ± 0.15 | 0.87 ± 0.13 | 0.205 |
| Δ at 3mo | −0.11 ± 0.21 | 0.01 ± 0.2 | −0.03 ± 0.21 | 0.147 | |
| Urine biomarkers @ | |||||
| 8-OHdG | Baseline | 66.09 (25.61, 93.36) | 80.46 (29.1, 107.14) | 79.83 (29.65, 110.22) | 0.818 |
| Δ at 3mo | 31.61 (0.3, 79.45) | −3.93 (−46.81, 3.89) | −1.05 (−41.38, 13.44) | 0.017 | |
| 8-isoprostane | Baseline | 11.14 (3.37, 21.78) | 11.34 (8.17, 20.74) | 11.88 (7.59, 26.73) | 0.818 |
| Δ at 3mo | −0.78 (−6.31, 12.72) | −4.63 (−13.31, −0.16) * | −2.88 (−8.18, 2.73) | 0.376 | |
| TAC | Baseline | 219.84 (151.79, 408.17) | 249.88 (197.86, 457.04) | 262.65 (179.62, 446.77) | 0.818 |
| Δ at 3mo | 32.71 (−99.69, 315.95) | −52.84 (−179.49, 22.5) | −23.18 (−136.51, 65.94) | 0.378 | |
| PGE2 | Baseline | 147.56 (105.38, 298.02) | 187.41 (133.92, 396.23) | 166.95 (119.72, 301.06) | 0.340 |
| Δ at 3mo | 75.02 (−32.71, 338.89) | −60.04 (−128.32, 1.19) * | −29.6 (−110.92, 75.02) | 0.102 | |
| IL-1β | Baseline | 0.59 (0.42, 0.63) | 0.55 (0.48, 0.64) | 0.57 (0.45, 0.62) | 0.611 |
| Δ at 3mo | −0.09 (−0.11, 0.02) | −0.06 (−0.17, 0.03) * | −0.06 (−0.14, 0.02) * | 0.894 | |
| IL-6 | Baseline | 0.7 (0.23, 3.82) | 0.69 (0.37, 2.14) | 0.69 (0.37, 2.02) | 0.795 |
| Δ at 3mo | −0.07 (−1.39, 1.44) | −0.15 (−0.57, 0.05) | −0.09 (−0.57, 0.1) | 0.894 | |
| IL-8 | Baseline | 1.73 (0.29, 4.07) | 1.22 (0.64, 9.47) | 1.43 (0.55, 3.53) | 0.611 |
| Δ at 3mo | −0.11 (−1.65, 0.67) | −0.39 (−2.91, 0.29) * | −0.37 (−1.65, 0.38) * | 0.894 | |
| TNF-α | Baseline | 1.19 (0.65, 1.3) | 1.06 (0.96, 1.31) | 1.16 (1, 1.29) | 0.990 |
| Δ at 3mo | −0.11 (−0.22, 0.04) * | −0.06 (−0.36, 0.03) | −0.1 (−0.22, 0.04) * | 0.537 | |
*: p < 0.05 when compared with baseline data. Δ: change in [specific variable]. @: units are all pg/mL, except ng/mL in 8-OHdG, and nmol/μL in TAC. GRA, global response assessment; BPH, benign prostatic hyperplasia; PSA, prostate-specific antigen; TPV, total prostate volume; TZI, transitional zone index; DWT, detrusor wall thickness; BWT, bladder wall thickness; IPSS, International Prostate Symptom Score; IPSS-S, IPSS storage subscore; IPSS-V, IPSS voiding subscore; QoL, quality of life; OABSS, overactive bladder symptoms score; BC, bladder capacity; Qmax, maximal urinary flow rate; cQmax, corrected maximal urinary flow rate; Vol, voided volume; PVR, post-void residual urine; VE, voiding efficiency; 8-OHdG, 8-hydroxy-2-deoxyguanosine; TAC, total antioxidant capacity; PGE2, prostaglandin E2; and TNF-α, tumor necrosis factor-α.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Jiang, Y.-H.; Lee, J.; Kuo, H.-C.; Wu, Y.-H. Urinary Inflammatory and Oxidative Stress Biomarkers as Indicators for the Clinical Management of Benign Prostatic Hyperplasia. Int. J. Mol. Sci. 2025, 26, 6516. https://doi.org/10.3390/ijms26136516
AMA Style
Jiang Y-H, Lee J, Kuo H-C, Wu Y-H. Urinary Inflammatory and Oxidative Stress Biomarkers as Indicators for the Clinical Management of Benign Prostatic Hyperplasia. International Journal of Molecular Sciences. 2025; 26(13):6516. https://doi.org/10.3390/ijms26136516
Chicago/Turabian StyleJiang, Yuan-Hong, Jimmy Lee, Hann-Chorng Kuo, and Ya-Hui Wu. 2025. "Urinary Inflammatory and Oxidative Stress Biomarkers as Indicators for the Clinical Management of Benign Prostatic Hyperplasia" International Journal of Molecular Sciences 26, no. 13: 6516. https://doi.org/10.3390/ijms26136516
APA StyleJiang, Y.-H., Lee, J., Kuo, H.-C., & Wu, Y.-H. (2025). Urinary Inflammatory and Oxidative Stress Biomarkers as Indicators for the Clinical Management of Benign Prostatic Hyperplasia. International Journal of Molecular Sciences, 26(13), 6516. https://doi.org/10.3390/ijms26136516
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
